Neuronetics Files to Sell 20.74M Shares of Common Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy STIM?
Neuronetics files to sell 20.74M shares of common stock for holders
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STIM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STIM
Wall Street analysts forecast STIM stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.515
Low
7.00
Averages
7.00
High
7.00
Current: 1.515
Low
7.00
Averages
7.00
High
7.00
About STIM
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Neuronetics Q4 2025 Earnings Call Highlights
- Leadership Transition: Neuronetics announced that Dan Reuvers will become CEO on March 23, bringing over 30 years of experience in medical devices, which is expected to enhance the company's growth in commercial healthcare.
- Strong Financial Performance: The company reported total revenue of $41.8 million in Q4 2025, an 86% increase driven primarily by the inclusion of Greenbrook operations, indicating robust market growth.
- Positive Operating Cash Flow: Neuronetics achieved positive operating cash flow in Q4, reflecting improved financial health and providing support for future investments and expansions.
- 2026 Outlook: Management provided revenue guidance for 2026 between $160 million and $166 million, indicating over 9% growth potential, with plans to drive further business growth through diversified TMS delivery models and the launch of new therapies.
See More
Neuronetics CEO Keith Sullivan to Retire, Dan Reuvers Appointed
- Executive Transition: Neuronetics announced that CEO Keith Sullivan will step down on March 23 and retire on March 31 after over five years in the role, a change that may impact the company's strategic direction and market confidence.
- New CEO Appointment: Dan Reuvers has been appointed as the new CEO effective March 23, bringing extensive experience from his previous role at Tactile Medical, which is expected to drive the company's next phase of expansion.
- Incentive Package: Neuronetics granted Reuvers 1.5 million restricted stock units as an inducement award, vesting over three years under the 2020 Inducement Incentive Plan, which aims to motivate his performance in the new role and attract investor interest.
- Market Reaction: In pre-market trading, Neuronetics' stock rose by 9.55% to $1.4899, reflecting positive market expectations regarding the new CEO and confidence in the company's future growth prospects.
See More
Neuronetics Q4 Earnings Beat Expectations
- Strong Earnings Report: Neuronetics reported a Q4 GAAP EPS of -$0.10, beating expectations by $0.01, indicating an improvement in profitability despite still being in the red.
- Significant Revenue Growth: The company achieved Q4 revenue of $41.78 million, representing an 85.8% year-over-year increase and surpassing market expectations by $0.94 million, reflecting robust demand and sales performance.
- Positive Stock Reaction: Following the earnings release, Neuronetics shares rose by 8%, suggesting increased investor confidence in the company's growth potential, which may attract more institutional investors.
- Optimistic Market Outlook: The company anticipates Q4 revenue to reach $41.8 million, further solidifying its market position in neuromodulation therapies and indicating sustained growth potential in the future.
See More
Neuronetics Appoints New CEO Effective March 2026
- Executive Change: Neuronetics has announced that Dan Reuvers will take over as president and CEO on March 23, 2026, succeeding Keith Sullivan, who will retire after five and a half years, indicating a potential shift in strategic direction for the company.
- Board Membership: Reuvers will also join the Board of Directors at that time, which not only enhances management stability but may also provide stronger leadership for future decision-making, helping the company stand out in the competitive medical device market.
- Market Reaction: Neuronetics' stock surged 17.65% in premarket trading to $1.60, reflecting investor optimism regarding the new CEO's appointment, which may signal increased confidence in the company's future growth prospects.
- Financial Outlook: Neuronetics expects Q4 revenue of $41.8 million, which not only highlights the company's growth potential in the market but may also provide financial support for the new CEO's strategic initiatives, further driving the company's development.
See More
Neuronetics to Release Q4 2025 Financial Results
- Earnings Release Announcement: Neuronetics plans to release its fourth quarter 2025 financial and operating results before market open on March 17, 2026, which is expected to provide investors with critical performance metrics and future outlook.
- Conference Call Details: The company will host a conference call at 8:30 a.m. Eastern Time on the same day to provide a detailed review of its financial results, enhancing investors' understanding of the company's operational status.
- Treatment Options Overview: Neuronetics' NeuroStar Advanced Therapy is FDA-approved for treating major depressive disorder (MDD) patients, particularly those who have not responded well to traditional antidepressants, highlighting its significance in the mental health field.
- Market Positioning: As a global leader in neuroscience, Neuronetics is committed to improving patients' quality of life by offering non-drug, non-invasive treatment options, further solidifying its competitive advantage in the medical technology market.
See More
Teradata Quarterly Earnings Beat Expectations
- Strong Earnings Performance: Teradata reported earnings of 74 cents per share, surpassing the analyst consensus estimate of 56 cents, indicating robust profitability that boosts investor confidence.
- Sales Growth: The company's quarterly sales reached $421 million, exceeding the analyst consensus estimate of $400.817 million, suggesting sustained strong market demand that could drive future business expansion.
- Stock Price Surge: Teradata shares jumped 16.5% to $34.07 in pre-market trading, reflecting a positive market reaction to the earnings report, which may attract more investor interest.
- Significant Market Impact: This earnings beat not only lifted the company's stock price but could also positively influence investor sentiment across the industry, further solidifying Teradata's market position in the data analytics sector.
See More
Neuronetics Q4 2025 Earnings Call Highlights
- Leadership Transition: Neuronetics announced that Dan Reuvers will become CEO on March 23, bringing over 30 years of experience in medical devices, which is expected to enhance the company's growth in commercial healthcare.
- Strong Financial Performance: The company reported total revenue of $41.8 million in Q4 2025, an 86% increase driven primarily by the inclusion of Greenbrook operations, indicating robust market growth.
- Positive Operating Cash Flow: Neuronetics achieved positive operating cash flow in Q4, reflecting improved financial health and providing support for future investments and expansions.
- 2026 Outlook: Management provided revenue guidance for 2026 between $160 million and $166 million, indicating over 9% growth potential, with plans to drive further business growth through diversified TMS delivery models and the launch of new therapies.
See More
Neuronetics CEO Keith Sullivan to Retire, Dan Reuvers Appointed
- Executive Transition: Neuronetics announced that CEO Keith Sullivan will step down on March 23 and retire on March 31 after over five years in the role, a change that may impact the company's strategic direction and market confidence.
- New CEO Appointment: Dan Reuvers has been appointed as the new CEO effective March 23, bringing extensive experience from his previous role at Tactile Medical, which is expected to drive the company's next phase of expansion.
- Incentive Package: Neuronetics granted Reuvers 1.5 million restricted stock units as an inducement award, vesting over three years under the 2020 Inducement Incentive Plan, which aims to motivate his performance in the new role and attract investor interest.
- Market Reaction: In pre-market trading, Neuronetics' stock rose by 9.55% to $1.4899, reflecting positive market expectations regarding the new CEO and confidence in the company's future growth prospects.
See More
Neuronetics Q4 Earnings Beat Expectations
- Strong Earnings Report: Neuronetics reported a Q4 GAAP EPS of -$0.10, beating expectations by $0.01, indicating an improvement in profitability despite still being in the red.
- Significant Revenue Growth: The company achieved Q4 revenue of $41.78 million, representing an 85.8% year-over-year increase and surpassing market expectations by $0.94 million, reflecting robust demand and sales performance.
- Positive Stock Reaction: Following the earnings release, Neuronetics shares rose by 8%, suggesting increased investor confidence in the company's growth potential, which may attract more institutional investors.
- Optimistic Market Outlook: The company anticipates Q4 revenue to reach $41.8 million, further solidifying its market position in neuromodulation therapies and indicating sustained growth potential in the future.
See More
Neuronetics Appoints New CEO Effective March 2026
- Executive Change: Neuronetics has announced that Dan Reuvers will take over as president and CEO on March 23, 2026, succeeding Keith Sullivan, who will retire after five and a half years, indicating a potential shift in strategic direction for the company.
- Board Membership: Reuvers will also join the Board of Directors at that time, which not only enhances management stability but may also provide stronger leadership for future decision-making, helping the company stand out in the competitive medical device market.
- Market Reaction: Neuronetics' stock surged 17.65% in premarket trading to $1.60, reflecting investor optimism regarding the new CEO's appointment, which may signal increased confidence in the company's future growth prospects.
- Financial Outlook: Neuronetics expects Q4 revenue of $41.8 million, which not only highlights the company's growth potential in the market but may also provide financial support for the new CEO's strategic initiatives, further driving the company's development.
See More
Neuronetics to Release Q4 2025 Financial Results
- Earnings Release Announcement: Neuronetics plans to release its fourth quarter 2025 financial and operating results before market open on March 17, 2026, which is expected to provide investors with critical performance metrics and future outlook.
- Conference Call Details: The company will host a conference call at 8:30 a.m. Eastern Time on the same day to provide a detailed review of its financial results, enhancing investors' understanding of the company's operational status.
- Treatment Options Overview: Neuronetics' NeuroStar Advanced Therapy is FDA-approved for treating major depressive disorder (MDD) patients, particularly those who have not responded well to traditional antidepressants, highlighting its significance in the mental health field.
- Market Positioning: As a global leader in neuroscience, Neuronetics is committed to improving patients' quality of life by offering non-drug, non-invasive treatment options, further solidifying its competitive advantage in the medical technology market.
See More
Teradata Quarterly Earnings Beat Expectations
- Strong Earnings Performance: Teradata reported earnings of 74 cents per share, surpassing the analyst consensus estimate of 56 cents, indicating robust profitability that boosts investor confidence.
- Sales Growth: The company's quarterly sales reached $421 million, exceeding the analyst consensus estimate of $400.817 million, suggesting sustained strong market demand that could drive future business expansion.
- Stock Price Surge: Teradata shares jumped 16.5% to $34.07 in pre-market trading, reflecting a positive market reaction to the earnings report, which may attract more investor interest.
- Significant Market Impact: This earnings beat not only lifted the company's stock price but could also positively influence investor sentiment across the industry, further solidifying Teradata's market position in the data analytics sector.
See More
